Neighborhood Behavior:  A Useful Concept for Validation of “Molecular Diversity” Descriptors
David E. Patterson,*, Richard D. Cramer,Allan M. Ferguson,Robert D. Clark, and, and Laurence E. Weinberger†
Journal of Medicinal Chemistry 1996 39 (16), 3049-3059
DOI: 10.1021/jm960290n

1. Uehling, D. E.; Nanthakamur, S. S.; Croom, D.; Emerson, D. L.; Leitner, P. P.; Luzzio, M. J.;et al.Synthesis, Topoisomerase I Inhibitory Activity, andin VivoEvaluation of 11-Azacamptothecin Analogs.J. Med. Chem.199538, 1106.(Table 2, with R2)Et; IC50data).
2. Strupczewski, J. T.; Bordeau, K. J.; Chiang, Y.; Glamkowski, E. J.; Conway, P. G.;et al.3-[[(aryloxy)alkyl]piperidinyl]-1,2-Benzisoxazoles as D2/5-HT2 Antagonists with Potential Atypical Antipsychotic Activity: AntipsychoticProfile of Iloperidone (HP873).J. Med. Chem.1995,38, 1119 (Tables 2 and 3 withn)3, X)O; ED50for inhibition of apomorphine-induced climbing).
3. Siddiqi, S. M.; Jacobson, K. A.; Esker, J. L.; Olah, M. E.; Ji, X.-d.;et al. Search for New Purine- and Ribose-Modified Adenosine Analogs as Selective Agonists and Antagonists at Adenosine Receptors.J. Med. Chem.1995,38, 1174 (Table 1, R2)H;K1(A1) values estimated from percent displacement and stereoisomers averaged as needed).
4, 5. Garratt, P. J.; Jones, R.; Tocher,D. A.; Sugden, D. Mapping the Melatonin Receptor. 3. Design and Synthesis of Melatonin Agonists and Antagonists Derived from2-Phenyltryptamines.J. Med. Chem.1995,38, 1132 (Tables 1 and 2).
6. Heyl, D. L.; Dandabuthla, M.; Kurtz, K. R.; Mousigian, C. OpioidReceptor Binding Requirements for the &-Selective Peptide Deltorphin I: Phe3Replacement with Ring-Substituted and HeterocyclicAmino Acids.J. Med. Chem.1995,38,1242 (Table 1; bindingK1to DPDPE).
7. Cristalli, G.; Camaioni, E.; Vittori, S.; Volpini, R.; Borea,P. A.;et al.2-Aralkynyl and 2-Heteroalkynyl Derivatives of Adenosine-5′-N-ethyluronamide as Selective A2a Adenosine Receptor Agonists.J. Med. Chem.1995,38, 1462.
8. Stevenson, G. I.; MacLeod, A. M.; Huscroft, I.; Cascieri, M. A.; Sadowski, S.; Baker, R. 4,4-DisubstitutedPiperidines: A New Class of NK1Antagonist.J. Med. Chem.1995,38, 1264 (Table 1).
9. Doherty, A. M.; Patt, W. C.; Edmunds, J. J.;Berryman, K. A.; Reisdorph, B. R.;et al.Discovery of a Novel Series of Orally Active Non-Peptide Endothelin-A (ETA) Receptor-SelectiveAntagonists.J. Med. Chem.1995,38, 1259 (Table 3; IC50ETA).
10. Penning, T. D.; Djuric, S. W.; Miyashiro, J. M.; Yu, S.; Snyder, J. P.;et al.Second-Generation Leukotriene B4Receptor Antagonists Related to SC-41930; Heterocyclic Replacement of the Methyl KetonePharmacophore.J. Med. Chem.1995,38, 858 (Table 1, all; LTB4receptor binding).
11. Lewis, R. T.; Macleod, A. M.; Merchant, K. J.;Kelleher, F.; Sanderson, I.;et al.Tryptophan-Derived NK1 Antagonists: Conformationally Constrained Heterocyclic Bioisosteres of theEster Linkage.J. Med. Chem.1995,38, 923 (Table 2, all).
12. Krystek, S. R.; Hunt, J. T.; Stein, P. D.; Stouch, T. R. 3D-QSAR ofSulfonamide Endothelin Inhibitors.J. Med. Chem.1995,38, 659 (Tables 1 and 2; dimethylated isoxazoles with substitution adjacent tooxygen).
13,14. Yokoyama, N.; Walker, G. N.; Main, A. J.; Stanton, J. L.; Morrissey, M.;et al. Synthesis and SAR of Oxamic Acid andAcetic Acid Derivatives Related to L-Thyronine.J. Med. Chem.1995,38, 695 (Table 1, all; nuclear IC50; Table 3, all; nuclear IC50).
15.Haadsma-Svensson, S. R.; Svensson, K.; Duncan, N.; Smith, M. W.; Lin, Ch.-H. C-9 and N-Substituted Analogs of cis-(3aR)-(-)-2,3,3a,4,5,9b-Hexahydro-3-propyl-1H-benz[e]indole-9-carboxamide: 5HT1A Receptor Agonists with Various Degrees of Metabolic Stability.J. Med.Chem.1995,38, 725 (Table 1, R1)CONH2; 5-HT1Abinding).
16. Tsutsumi, S.; Okonogi, T.; Shibahara, S.; Ohuchi, S.; Hatsushiba, E.;et al. Synthesis and Structure-Activity Relationships of PeptidylR-Keto Heterocycles as Novel Inhibitors of Prolyl Endopeptidase.J.Med. Chem.1994,37, 3492 (Table 2, X)CH2CH2;IC50).
17. Chang, L. L.; Ashton, W. T.; Flanagan, K. L.; Chen, T.-B.; O’Malley, S. S.;et al.Triazolinone Biphenylsulfonamides as Angiotensin II Receptor Antagonists with High Affinity for Both the AT1and AT2Subtypes.J. Med. Chem.1994,37, 4464 (Table 1, R3)(2-Cl)C6H5;AT1(rabbit aorta) IC50).
18. Rosowsky, A.; Mota, C. E.; Wright, J. E.; Queener,S. F. 2,4-Diamino-5-chloroquinazoline Analogs of Trimetrexate and Piritrexim: Synthesis and Antifolate Activity.J. Med. Chem.1994,37, 4522 (Table 2; rat liver IC50).
19. Thompson, S. K.; Murthy, K. H. M.; Zhao, B.; Winborne, E.; Green, D. W.;et al.Rational Design,Synthesis, and Crystallographic Analysis of a Hydroxyethylene-Based HIV-1 Protease Inhibitor Containing a Heterocyclic P1′-P2′AmideBond Isostere.J. Med. Chem.1994,37, 3100 (Table 2, X)Boc; apparentKi).
20. Depreux, P.; Lesieur, D.; Mansour, H. A.; Morgan, P.;et al.Synthesis and Structure-Activity Relationships of Novel Naphthalenic and Bioisosteric Related Amidic Derivatives as MelatoninReceptor Ligands.J. Med. Chem.1994,37, 3231 (Table 1, R1)7-OCH3,R2)H,x)1, R3)H;KD).